CAU
OCUL icon

Caxton Associates (UK)’s Ocular Therapeutix OCUL Stock Holding History

Caxton Associates (UK)’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-17,932
Closed -$218K – 941
2025
Q4 		$218K Buy
+17,932
New +$218K ﹤0.01% 699
2025
Q2 		– Sell
-33,821
Closed -$248K – 843
2025
Q1 		$248K Buy
+33,821
New +$260K 0.01% 672

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Caxton Associates (UK)'s OCUL Position: Q1 2026 in Review

Caxton Associates (UK) sold out of Ocular Therapeutix (OCUL) in Q1 2026, closing a stake of 17,932 shares — an estimated $218K sold.

Caxton Associates (UK) first reported a position in OCUL in Q1 2025 and held it in 2 quarters. The position peaked at $248K in Q1 2025. 271 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

  • Caxton Associates (UK) reported no remaining Ocular Therapeutix position as of Q1 2026 after selling out during the quarter.
  • Caxton Associates (UK) sold 17,932 Ocular Therapeutix shares in Q1 2026, an estimated $218K.
  • Caxton Associates (UK) first reported a position in Ocular Therapeutix in Q1 2025 and held it in 2 quarters.
  • Caxton Associates (UK)'s Ocular Therapeutix position peaked at $248K in Q1 2025.
  • 271 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Caxton Associates (UK)'s 13F filing for Q1 2026, filed 14 May 2026.